Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD To Board Of Managers

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD To Board Of Managers

KALAMAZOO, Mich., Oct. 23, 2014 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today that it has appointed Robert L. Zerbe, MD to its Board of Managers.  Dr. Zerbe co-founded and is chief executive officer of QuatRx Pharmaceuticals Company, a venture-backed drug development company that developed the recently launched product for postmenopausal dyspareunia, Osphena®. Prior to QuatRx, he served as Senior Vice President of Worldwide Clinical Research and Development of Pfizer (formerly Parke-Davis), where he led the clinical development programs for Neurontin® and Lipitor®.

Robert L. Zerbe, MD joins Metabolic Solutions Development Co. board of managers. Zerbe is CEO of QuatRx Pharmaceuticals.
"We are extremely pleased to have recruited a pharmaceutical executive of Bob's caliber to join our Board," said Stephen Benoit, MSDC's chief executive officer. "The breadth and depth of his clinical development experience, which includes the most successful pharmaceutical product ever developed, and leadership of a successful venture-backed drug development company will add significantly to the strategic development of our mid-stage clinical pipeline."

"It's a pivotal time at MSDC, as the Company prepares to begin Phase 2 studies in NASH and polycystic kidney disease in 2015, and the research team nears a critical milestone in the discovery of new insulin sensitizers to treat type 2 diabetes," said Dr. Zerbe. "As such, I'm very much looking forward to joining the Board and to working with the management team to execute its research and clinical development strategies."

Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Currently, he is Chairman of the Board of Aastrom Biosciences, a public specialty biologics company developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.

About Metabolic Solutions Development Company

Metabolic Solutions Development Company ( is a biopharmaceutical company developing first in class oral therapeutics for the treatment of diseases associated with metabolic dysfunction, including NASH, polycystic kidney disease, neurodegenerative disease (e.g., Parkinson's) and diabetes.

Photo -

SOURCE Metabolic Solutions Development Company, LLC

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.